Consumer Staples • Retail-Drug Stores and Proprietary Stores
$90.33 ▲ +0.38
(+0.42%)
MKT CAP: $115.53B • VOL: 10.23M
52W L $70 52W H $111
CVS // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $402.07B | $372.81B | $357.78B |
| YoY Revenue Growth % | +7.8% | +4.2% | — |
| Gross Profit | $180.90B | $166.52B | $157.42B |
| Gross Margin % | 45.0% | 44.7% | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $4.66B | $8.52B | $13.74B |
| Operating Margin % | 1.2% | 2.3% | 3.8% |
| Net Income (GAAP) | $1.77B | $4.61B | $8.34B |
| EBITDA (Normalized) | $6.93B | $10.74B | $26.62B |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $10.64B | $9.11B | $13.43B |
| Capital Expenditures (CapEx) | $2.83B | $2.78B | $16.10B |
| Free Cash Flow (FCF) | $7.81B | $6.33B | -$2.67B |
| FCF Margin % | 1.9% | 1.7% | -0.7% |
| Return on Invested Capital (ROIC %) | 2.5% | 4.6% | 4.2% |
| Cash & Short-Term Equivalents | $8.45B | $8.59B | $47.23B |
| Total Debt (Short + Long Term) | $80.17B | $79.87B | $100.46B |
| Total Stockholders' Equity | $75.21B | $75.56B | $206.08B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CVS.